cd3

Anti-Mouse CD3 Antibody (17A2) is a murine IgG2b class antibody targeting CD3, which can be used to study TCR signaling, T cell activation and antigen recognition.

Cibisatamab is a T-cell bispecific antibody that acts as a T-cell splicer.Cibisatamab targets carcinoembryonic antigen (CEA) on cancer cells and CD3 on T-cells, and triggers T-cell killing when the CEA on the surface of the cancer cells ranges from intermediate to high levels.Cibisatamab may be used to study solid cancers such as colorectal cancer.

Mosunetuzumab (BCT-4465A) is a humanized antibody based on immunoglobulin G1 that targets CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used to study relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) and refractory follicular lymphoma.

Teplizumab (MGA-031) is a humanized monoclonal antibody targeting CD3 that slows the loss of beta cell function and is used to treat type 1 diabetes.

Tidutamab (XmAb-18087) is a humanized bispecific antibody targeting the growth inhibitory receptor 2 (SSTR2) and T-cell binding domain (CD3) with antitumor activity for the study of gastric neurosecretory tumors.

Epcoritamab (GEN3013) is a novel subcutaneous CD3xCD20 bispecific T-cell binding antibody that activates T-cells and directs them to kill malignant CD20(+) B-cells for the study of relapsed or refractory large B-cell lymphoma.

Anti-Human CD3 Antibody (UCHT1) is a monoclonal antibody targeting human CD3 and can be used in immunological research.

Anti-CD3 Antibody (OKT-3, humanized) is a humanized OKT3-derived anti-CD3 antibody developed based on Muromonab-CD3 (OKT3, T76719), with reduced immunogenicity relative to the original murine antibody. Anti-CD3 Antibody (OKT-3, humanized) is applicable to immunological research involving T-cell receptor signaling, lymphocyte activation, and immune modulation in translational and preclinical experimental systems.

Anti-Mouse CD3ε Antibody (145-2C11) is an antibody inhibitor targeting CD3ε in Armenian hamsters, derived from mice, with the isotype control being Armenian hamster IgG, Isotype Control. CD3ε participates in TCR formation and plays a role in T lymphocyte activation and antigen recognition.

Anti-Mouse CD3ε Antibody (KT3) is an inhibitory antibody derived from rats, targeting mouse CD3ε, which can promote thymocyte proliferation and is suitable for immunology-related research.

Muromonab (OKT3) is a murine monoclonal antibody targeting CD3 receptors, blocking all cytotoxic T-cell functions. It reverses acute organ transplant rejection and is used in studies of acute graft rejection.

The compound M701 is a bispecific antibody that targets CD3 on T cells and EpCAM on tumor cells, aiming to stimulate T cell-mediated tumor cell death. It is being developed for the treatment of malignant ascites by redirecting T cells to attack tumors expressing EpCAM. [Molecular weight: 125.84 kDa]

NCD38 is a selective LSD1 (lysine-specific demethylase 1) inhibitor that activates super-enhancers and myeloid cell development programmes, exhibiting anti-leukaemia activity.

Anti-Mouse TIM-1/CD365 Antibody (3D10) is a rat-derived monoclonal antibody that specifically binds to and blocks T-cell immunoglobulin and mucin domain-containing protein 1 (TIM-1). Anti-Mouse TIM-1/CD365 Antibody (3D10) is primarily used for functional blocking experiments both in vivo and in vitro. Anti-Mouse TIM-1/CD365 Antibody (3D10) exhibits dual regulatory effects in vivo: it exacerbates lesion development in atherosclerosis models while effectively reducing disease severity in graft-versus-host disease (GVHD) models.

Anti-Mouse CD37 Antibody (252-3) is a monoclonal inhibitory antibody against mouse CD37, suitable for use in life science research.

Anti-Mouse CD3E Antibody (500A2) is a monoclonal inhibitory antibody targeting the mouse CD3ε subunit. CD3ε is a 20-kD transmembrane protein belonging to the immunoglobulin superfamily, primarily expressed on the surface of T cells and NK-T cells, and exhibiting differential expression at various stages of thymocyte differentiation. CD3ε can assemble with CD3δ, CD3γ, and CD3ζ chains, as well as TCR α/β or γ/δ chains, to form TCR complexes. By recognizing peptide-MHC antigen complexes, CD3 plays a critical role in TCR signal transduction, T-cell activation, and antigen recognition.

Alogliptin-13CD3 is the deuterium-labeled Alogliptin. Alogliptin (T6192) is a selective inhibitor of DPP-4.

CD3254 is a selective and potent retinoid X receptor-like (RXR) agonist that inhibits neuronal cell death with OGD/reoxygenation.

CD38 inhibitor 1 is a potent CD38 inhibitor that is effective against human CD38 (IC₅₀ value is 7.3 nM) and mouse CD38 (IC₅₀ value is 1.9 nM).

CD39-IN-1 (Compound 338) is a selective small molecule CD39 inhibitor with an IC₅₀ value of 68.7 nM. It exhibits antiproliferative activity against tumor cells and can inhibit the eATP hydrolysis mediated by CD39 in the ATP-adenosine pathway. CD39-IN-1 shows potential for use in cancer research.

CD38-IN-5 (compound 1) is a CD38 inhibitor that selectively inhibits CD38 hydrolase with an IC₅₀ of 4.0 μM but does not inhibit CD38 cyclase. It effectively enhances NK cell-mediated tumor cytotoxicity and increases NADH+ and IFNγ levels in activated peripheral blood mononuclear cells (PBMC). CD38-IN-5 is applicable in cancer research.

UCD38B HCl is a cell-permeable intracellular uPA inhibitor that acts by killing proliferative and non-proliferative high-grade glioma cells by programmed necrosis.

CD38 inhibitor 2 is an effective CD38 inhibitor (IC₅₀ = 10–100 nM) suitable for cancer and immunology research.

CD33 splicing modulator 1 (Compound 1) is a CD33 splicing modulator that targets the CD33/Siglec 3 myeloid cell surface receptor, known for regulating microglial cell activity, and holds potential for studying neurodegenerative diseases such as Alzheimer's disease.